• The tacrolimus@ zeolitic imidazolate framework-8 nanoparticles (240 min retention) synergistically enhanced transcorneal delivery of FK506. In a rabbit IMGR model, the FK506@ZIF-8/HTCC eye drop significantly prolonged graft survival, reduced inflammatory infiltration, and outperformed conventional FK506 eye drops, highlighting its therapeutic potential for overcoming corneal drug delivery barriers. In summary, the FK506@ZIF-8/HTCC sol hold great promise for preventing high-risk keratoplasty rejection in clinic in the future.
Jia et al. (Fri,) studied this question.